The generation and maintenance of serum alloantibody

Donor-specific alloantibodies (DSA) mediate hyperacute and acute antibody-mediated rejection (AMR) which can lead to early graft damage and loss and are also associated with chronic AMR and reduced long-term graft survival Such alloantibodies can be generated by previous exposure to major histocompatibility (MHC)antigens (usually via blood transfusions previous allografts or pregnancy) or can occur de novo after transplantation Recent studies also suggest that non-MHC antibodies including those recognising major histocompatibility complex class l-related chain A (MICA) MICB, vimentin angiotensin II type I receptor may also have an adverse impact on allograft outcomes In this review we consider how the dose route and context of antigen exposure influences DSA induction and describe factors which control the generation maintenance and survival of alloantibody-producing plasma cells Finally we discuss the implications of these variables on therapeutic approaches to DSA